Treatment approach to patients with r/r MCL. ∗High-risk refers to MCL with TP53 mutations and/or blastoid or pleomorphic morphology and/or Ki-67 ≥50% (≥30% in select cases). BCL2i, B-cell lymphoma 2 inhibitor; CAR-T, chimeric antigen receptor T-cell therapy; CD20Ab, CD20 monoclonal antibody; CNS, central nervous system.

Treatment approach to patients with r/r MCL. ∗High-risk refers to MCL with TP53 mutations and/or blastoid or pleomorphic morphology and/or Ki-67 ≥50% (≥30% in select cases). BCL2i, B-cell lymphoma 2 inhibitor; CAR-T, chimeric antigen receptor T-cell therapy; CD20Ab, CD20 monoclonal antibody; CNS, central nervous system.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal